Researchers at Boston University and Massachusetts General Hospital developed a bi-hormonal artificial pancreas called the Bionic Pancreas to help manage diabetes. It consists of a continuous glucose monitor and insulin and glucagon infusion pumps that automatically adjust medication levels every 5 minutes based on the person's needs. The Bionic Pancreas is expected to be approved by the FDA and available for purchase in 2017. It aims to make diabetes management easier by adapting insulin dosing to the individual's daily requirements without needing anything other than their weight. However, there are still limitations including potential pump or sensor failures, low battery power, and delayed drug absorption.

1. BIONIC PANCREAS

3. Introduction
History
Bi-Harmonal Automatic Device
Technique
Advantages
Limitations

6. Dr. Edward Damiano & Dr Steven Russels
of Boston University / Massachusetts
General Hospital.
In Year 2005 : 1st Started testing it in pigs.
It is still not FDA approved.
 Most likely 2017 Approval

8. Bionic pancreas will bring the ilet to
market in the name of
“ MEDTRONiCS Mini Med 640G “
Expected to launch in April 2017 after
FDA approval

11. 1. Control
2. Continuous Glucose monitor
3. Insulin and glucagon infusion pump

14. “It is a platform that makes a GREAT drug
BETTER “shared by Dr.Diamino
Past studies of automated insulin delivery
have repeatedly shown that insulin needs
vary dramatically from day to day and
night to night

15. People with type 1 may require
 10 units of insulin on Monday night
 7 units on Tuesday
 13 units on wensday
•Systems like Bionic Pancreas can adapt to
those variations in insulin needs
automatically every 5 mins in personalized
insulin delivery

16. The bionic pancreas has some other exciting
advantages
• Only BODY WEiGHT information is needed to begin
Dosing insulin and Glucagon
• The System quickly adapts with in a day to whatever
specific person needs.

17. Low batteries
Delayed action of subcutaneous infused
insulin
Incorrect adaptations of controlled algorithms
Sensor unavailability due to loss of
communications or non compliance of the pt.

18. Infusion pump
•infusion set occlusion
•Insulin set leakage or dislocation.
•Hardware/ software failures
•Bi harmonal system
•Switching of insulin and glucagon.